Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 685 across all filing types
Latest filing 2025-01-30 Interim / Quarterly Rep…
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 456.0KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'Quarterly Cash Flow Statement & Operational Highlights' for the quarter ended December 2024. It includes detailed financial data such as cash flows from operating, investing, and financing activities, cash balances, payments to related parties, and estimated cash available for future operations. It also contains operational highlights including regulatory approvals, clinical trial updates, patent grants, and conference presentations. The presence of the Appendix 4C quarterly cash flow report, which is a regulatory requirement for ASX-listed entities to report quarterly cash flows, confirms this is a quarterly report. The document is comprehensive, with substantive financial data and analysis for a period shorter than a full fiscal year, fitting the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report or a certification, but contains actual financial statements and operational commentary for the quarter.
2025-01-30 English
Patient Dosing Complete in Phase II ABSSSI Trial of R327G 3 pages 303.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement detailing the dosing completion and preliminary results of a Phase II clinical trial for a pharmaceutical product (RECCE 327 topical gel). It includes clinical trial progress, safety and efficacy highlights, future trial plans, and market opportunity information. There are no financial statements, detailed financial analysis, or regulatory filings such as 10-K or interim reports. The content is a corporate update on clinical trial progress and future plans, typical of a Capital/Financing Update or general corporate announcement. However, since it focuses on clinical trial progress and regulatory trial plans rather than fundraising or capital structure changes, it aligns best with a Regulatory Filings (RNS) category, which is the fallback for miscellaneous regulatory or corporate announcements that do not fit other categories. The document length (6745 characters) and detailed content confirm it is not a brief report publication announcement or a simple notice. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-01-20 English
Regulatory Approval for Registrational Phase 3 R327G Trial 3 pages 278.4KB
Regulatory Filings
2024-12-08 English
Trading Halt 2 pages 589.2KB
Regulatory Filings
2024-12-04 English
Presentation - Ord Minnett Biotech & MedTech Conference 35 pages 2.7MB
Regulatory Filings
2024-11-27 English
Australia Patent Granted for RECCE Anti-Infectives 3 pages 229.7KB
Regulatory Filings
2024-11-25 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.